is glp 1 an injection GLP-1 Injections Semaglutide for Chronic Weight Management

Medicare beneficiaries who qualify for other FDA-approved indications, such as reducing cardiovascular risk in adults with established CV disease and obesity or overweight will continue to access the drug through their normal Part D benefits

Nausea and vomiting are the most common side effects of Lixisenatide in the first stage of gastrointestinal adverse reactions

Addressing the Plateau Many people experience a honeymoon phase with medications like Ozempic or Wegovy, where the weight drops quickly at first and then levels off

34% of GLP-1 users discontinue within the sample period

(2025) Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis

According to FDA labeling, the common side effects include: Gastrointestinal effects (with frequencies varying by dose): Nausea (12-30% of patients, often most prominent during dose escalation) Diarrhea (7-22%) Vomiting (2-10%) Constipation (5-17%) Abdominal pain or discomfort (5-10%) Decreased appetite (5-10%) Dyspepsia/indigestion (2-9%) Gastroesophageal reflux disease (1-5%, more common in weight management indication) Eructation/belching (more common in weight management indication) These gastrointestinal symptoms typically occur early in treatment or following dose increases and often diminish over time as the body adjusts to the medication